Innomedica is currently running

Ulcerative colitis drug trial

Innomedica Medical Center invites patients with moderate to severe active ulcerative colitis to participate in a clinical drug trial. The purpose of the study is to determine the safety and efficacy of a new experimental drug (MORF-057).

What does the study look at?

During the study, it is observed how the organism assimilates, distributes and finally gets rid of the drug under study (pharmacokinetics). It also examines how the drug under study affects the body (pharmacodynamics).

How is the study drug administered?

The new investigational drug comes in capsules that are taken orally on a daily basis.
The patient is under the careful supervision of our doctors throughout the entire study period.

To get more information about the study, call us at 6109434  or fill out the form below and we will contact you.

I would like more information.

Main criteria for inclusion in the study:

  • Age: 18-85 years old
  • The patient has had a diagnosis of ulcerative colitis for at least 3 months, supported by signs, symptoms, and endoscopic and histological examination
  • Involvement of the disease at least 15 cm from the anal area
  • Active disease regardless of previous treatment

During the examination, a team of doctors and nurses will closely monitor your health. All study drugs and analyzes related to the study are free for you. Participation in the study is unpaid, but you may be reimbursed for travel expenses incurred during participation.

Participation in the study is voluntary. Contacting us does not obligate you to participate in the study. 

*The study has been coordinated with the Human Research Ethics Committee of the Health Development Institute and the Medicines Agency. Regulation No. 23 of the Minister of Social Affairs of 17.02.2005 “Procedure and execution of a clinical trial of a medicinal product” obliges to inform that “it is a scientific study that may involve a risk to the participant’s health”.

Scroll to Top